# DFT383 in Pediatric Participants With Nephropathic Cystinosis

> **NCT06910813** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (estimated)

## Conditions studied

- Nephropathic Cystinosis

## Interventions

- **GENETIC:** DFT383

## Key facts

- **NCT ID:** NCT06910813
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2031-03-14
- **Final completion:** 2044-03-14
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910813, "DFT383 in Pediatric Participants With Nephropathic Cystinosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06910813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*